Anti-cancer effects of deguelin on human leukemia K562 and K562/ADM cells In Vitro

Abstract

In order to investigate the anti-cancer effects of deguelin and on K562 and K562/ADM cells in vitro and the underlying molecular mechanism and compare the cytotoxicity of deguelin on K562, K562/ADM cells and human peripheral blood mononuclear cells (PBMCs). The effects of deguelin on cell proliferation were assessed by MTT assay. Apoptosis were detected by Annexin V/PI double-labeled cytometry. The effects of deguelin on the cell cycle were studied by a propidium iodide method. Our study showed that deguelin inhibited the proliferation of K562 cell and K562/ADM cell in a time- and dose-dependent manner and had minimal effects on normal human peripheral blood mononuclear cells. The ratio of IC₅₀ value of deguelin of 24 h on K562/ADM cells to K562 cells was only 1.27, which was significantly lower than the ratio of IC₅₀ value of ADM (higher than 20). Deguelin could induce apoptosis of K562 cells and K562/ADM cells. K562 cells were arrested at G₂/M phase while K562/ADM cells were arrested at G₀/G₁ phase. Our results suggested that deguelin was a novel anti-leukemia agents with high efficacy and low toxicity and it is also a promising agent for reversing drug resistance.

Keywords

deguelin / K562 cell / K562/ADM cell / apoptosis / cell cycle

References

[1] McWilliamsA., LamS.. New approaches to lung cancer prevention. Curr Oncol Rep, 2002, 4: 487-94

[2] AndersonW. F., UmarA., VinerJ. L., et al.. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des, 2002, 8: 1035-62

[3] van SanwijkN., DalesioO., PastorinoU., et al.. EURO-SCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst, 2000, 92: 977-86

[4] LippmanS. M., SpitzM. R.. Lung cancer chemoprevention: an integrated approach. J Clin Oncol, 2001, 19(18Suppl): 74S-82S

[5] PendyalaL., SchwartzG., Bolanowska-HigdonW., et al.. Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Cancer Epidemiol Biomarkers Prev, 2001, 10: 269-72

[6] GreenwaldP.. Cancer prevention clinical trials. J Clin Oncol, 2002, 20(18Suppl): 14S-22S

[7] ChunK. H., KosmederJ. W., SunS., et al.. Effect of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst, 2003, 95: 291-302

[8] LiuH. L., ChenY., CuiG.H., et al.. Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt’s lymphoma Daudi cells in vitro. Acta Pharmacologica Sinica, 2005, 26(7): 873-880

[9] MurilloG., SaltiG. I., KosmederJ. W.2nd, et al.. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer, 2002, 38: 2446-2454

[10] UdeaniG. O., GerhauserC., ThomasC. F., et al.. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res, 1997, 57(16): 3424-3428

[11] BennerS. E., LippmanS. M., HongW. K.. Chemoprevention strategies for lung and upper aerodigestive tract cancer. Cancer Res, 1992, 52(9Suppl): 2758s-2763

[12] RaoC. V., RivensonA., SimiB., et al.. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res, 1995, 55: 259-266

[13] UdeaniG. O., ZhaoG. M., ShinY. G., et al.. Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats. Gancer Chemother Pharmacol, 2001, 47: 263-268

[14] FangN., CasidaJ. E.. Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc Natl Acad Sci USA, 1998, 95(7): 3380-3384

[15] MehtaR. G., PezzutoJ. M.. Discovery of cancer preventive agents from natural products:from plants to prevention. Curr Oncol Rep, 2002, 4(6): 478-486

[16] HollemanA., den BoerM. L., KazemierK. M., et al.. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood, 2005, 106(5): 1817-1823